Foster City, California, United States In 1987 was created Gilead Sciences, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Foster City. The venture was found in North America in United States.
We also calculated 4 valuable employees in our database.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Gilead Sciences, startups are often financed by Penn Medicine Co-Investment Fund, Parker Institute for Cancer Immunotherapy, Lilly Asia Ventures. The meaningful sponsors for the fund in investment in the same round are Be The Match BioTherapies, Yonghua Capital, Ping An Ventures. In the next rounds fund is usually obtained by Penn Medicine Co-Investment Fund, Be The Match BioTherapies, venBio Select Advisor.
Deals in the range of more than 100 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Gilead Sciences works on 4 percentage points more the average amount of lead investments. The high activity for fund was in 2019. The increased amount of exits for fund were in 2019.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Nanotechnology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, AlloVir, Lyndra Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Related Funds
| Fund Name | Location |
| Almaworks | New City, New York, United States |
| Amity Supply | New York, New York, United States |
| Arcapita Ventures | Atlanta, Georgia, United States |
| Ascent Hydrogen Fund | - |
| Blibli | Indonesia, Jakarta, Jakarta Raya |
| Costone | Beijing, China, Huairou |
| FONGIT | Geneva, Geneve, Switzerland |
| Greylock Partners | California, Menlo Park, United States |
| Guolian Securities | Anhui, China, Wuxi |
| Hydrazine Capital | California, Mountain View, United States |
| Intelligent Fund of Funds | - |
| Meltwind Advisory | Cambridge, Cambridgeshire, United Kingdom |
| Northrop Grumman | Falls Church, United States, Virginia |
| Pinnacle Enterprise Fund | - |
| Pipilu | Beijing, Beijing, China |
| Shanda Interactive Entertainment Limited | China, Shanghai |
| Suzhou Hexing Chuangtou | China, Jiangsu, Suzhou |
| Temasek Holdings | Central Region, Singapore, Singapore |
| Whitman Capital | California, Palo Alto, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Tentarix Biotherapeutics | $35M | 06 Sep 2023 | La Jolla, California, United States | ||
Kyverna Therapeutics | $60M | 03 Aug 2023 | Berkeley, California, United States | ||
Exavir Therapeutics | $4M | 23 May 2022 | - | ||
Curebase | $40M | 05 May 2022 | San Francisco, California, United States | ||
Lyndra Therapeutics | $60M | 24 Jun 2021 | Watertown, Massachusetts, United States | ||
Vaccitech | $168M | 17 Mar 2021 | Oxford, England, United Kingdom | ||
| $46M | 15 Jul 2020 | Cambridge, Massachusetts, United States | |||
| $100M | 30 Jun 2020 | Cambridge, Massachusetts, United States | |||
Vineti | $35M | 05 Feb 2020 | San Francisco, California, United States |
– Lyndra Therapeutics from Watertown, MA develops a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options.
– The company closed a $60.5m Series C financing round.
– The round was led by new investor, AIG Investments, an affiliate of American International Group with participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Ventures and the Catalytic Impact Foundation with ImpactAssets, and existing investors Polaris Partners, Invus, Quark Venture, Mass General Brigham Ventures, HOPU Investments, and Gilead Sciences, Inc.
– Vaccitech Ltd from Oxford develops a proprietary platform to treat and prevent infectious diseases and cancer.
– The company raised $168m in Series B funding.
– The round was led by M&G Investment Management and attracted new investor Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others.
– The new investment will be used to develop the company’s pipeline of product candidates targeting infectious disease (including MERS coronavirus and Herpes Zoster) and cancer (including non-small cell lung cancer).
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Tentarix Biotherapeutics | $35M | 06 Sep 2023 | La Jolla, California, United States | ||
Kyverna Therapeutics | $60M | 03 Aug 2023 | Berkeley, California, United States | ||
Exavir Therapeutics | $4M | 23 May 2022 | - | ||
Curebase | $40M | 05 May 2022 | San Francisco, California, United States | ||
Lyndra Therapeutics | $60M | 24 Jun 2021 | Watertown, Massachusetts, United States | ||
Vaccitech | $168M | 17 Mar 2021 | Oxford, England, United Kingdom | ||
| $46M | 15 Jul 2020 | Cambridge, Massachusetts, United States | |||
| $100M | 30 Jun 2020 | Cambridge, Massachusetts, United States | |||
Vineti | $35M | 05 Feb 2020 | San Francisco, California, United States |
